About Us
Browse:
Our mission
/content/moderna-corp-aem/en-hk/about-us/our-mission
Contact Moderna
/content/moderna-corp-aem/en-hk/contact-moderna
tab1
To deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.
Our Values
Moderna people hold a deep sense of responsibility for each other, patients, the environment and our local communities. Our people live our Values every day.
Bold
Bold
Collaborative
Collaborative
Relentless
Relentless
Curious
Curious

Meet the US leadership team

  • text-center
Stéphane Bancel
Chief Executive Officer
linkedin
https://www.linkedin.com/in/st%C3%A9phane-bancel-8185251

Stéphane Bancel has been Moderna's Chief Executive Officer since October 2011 and has served on Moderna’s board of directors since March 2011. Prior to joining Moderna, Mr. Bancel was the Chief Executive Officer of the French diagnostics company bioMérieux SA for five years. From July 2000 to March 2006, he held various positions at Eli Lilly and Company, including Managing Director, Belgium, and Executive Director, Global Manufacturing Strategy and Supply Chain. Before his tenure at Eli Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux.

In addition to his role at Moderna, Mr. Bancel is a board member of Generate:Biomedicines and a Venture Partner at Flagship Pioneering. He holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School.

Mr. Bancel was nominated Chevalier of the Legion d'honneur in 2022, the highest recognition in France, and member of the US National Academy of Engineering in 2024.

default
card, right

We’re making biotech history

Messenger RNA is not new technology, but we are discovering new ways to use it to treat and prevent illnesses and diseases. Since our founding in 2010, we have worked to build the industry's leading mRNA technology platform.
false
false
Our big moments
h2
2010
Moderna incorporates
h3
Moderna’s name combines the words "modified" and "RNA," which happens to contain the word "modern.”
2011
Operations started
h3
Moderna begins research into the production of mRNA medicines. Stéphane Bancel joins as founding CEO.
2014
Expansion
h3
New headquarters and labs open in Cambridge, MA.
2015
First human dose of flu vaccine
h3
Moderna initiates first-in-human dose of an mRNA vaccine (mRNA-1440), an H10N8 flu vaccine candidate.
2016
New lease signed
h3
Lease signed to build 200,000-square-foot GMP mRNA clinical manufacturing facility in Norwood, MA.
2017
First human dose of multivalent vaccine
h3
Moderna initiates first-in-human dosing for mRNA-1653, a combination vaccine with the potential to protect against more than one disease–human metapneumovirus (hMPV virus) and parainfluenza virus.
2018
New facility opens
h3
Moderna opens its state-of-the-art clinical development site in Norwood, MA.
2019
First antibody encoded by mRNA
h3
Moderna announces dosing of the first antibody encoded by mRNA in a clinical trial.
2020
CDC recommendation
h3
The U.S. Centers for Disease Control and Prevention votes to recommend the use of the Moderna COVID-19 vaccine in people 18 years of age and older in the U.S.
2022
Moderna receives full approval for COVID-19 vaccine by U.S. FDA
h3
The U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for SPIKEVAX (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 18 years of age and older in the U.S.
2022
Moderna Hong Kong established
h3
Establishment of Moderna Hong Kong Co., Ltd.